ANGANY Genetics

Sotteville-lès-Rouen, France

ANGANY Genetics

Sotteville-lès-Rouen, France
SEARCH FILTERS
Time filter
Source Type

The invention relates to a plant cell comprising a DNA molecule including at least one heterologous nucleotide sequence coding for a pre-protein of a pectate lyase selected from among Amb a 1, the alpha subunit of Amb a 1, the beta subunit of Amb a 1 and Amb a 1 homologues, and functionally bound to a strong promoter.


A plant cell including a DNA molecule having at least one heterologous nucleotide sequence encoding a preproprotein of a pectate lyase chosen from Amb a 1, the alpha subunit of Amb a 1, the beta subunit of Amb a 1, and homologs of Amb a 1, functionally bound to a strong promoter.


Dublin, Sept. 14, 2017 (GLOBE NEWSWIRE) -- The "Global Virus Like Particles Market & Clinical Trial Insight 2023" clinical trials has been added to Research and Markets' offering. Vaccination is considered the most cost effective way to control the pathogens and prevent the diseases both in humans and veterinary field. The vaccines based on virus like particles represent one of the most appealing and cost effective approaches due to the intrinsic immunogenic properties as well as high safety profile. The virus like particles also offers several other advantages against the emerging viruses and these are virus like particles are not live viruses and thus manufacturing process offers a safer environment for the operators. The modern approach for the development of vaccines is focused on the identification of the molecular entities from different organisms as candidates which can mimic the role of viruses. This approach is certainly safer and produces lesser or no side effects after the vaccination process. Virus-like particles are one of such candidates which have shown most promising results and are currently involved in treating a wide range of diseases. Virus-like particles are composed of the characteristic building proteins of a virus which mimic the properties of the infectious viruses but lack the viral genome. Therefore, Virus like particles became an extremely impressive and promising vaccine candidates due to the presence of virus like but yet non-infective properties in them. Thus, the viruses like particle based vaccines are potentially safer candidates for developing vaccines. Furthermore, Virus like particles are able to induce both innate and adaptive immune responses in humans. Most of the virus like particle based vaccines are derived from the bacteria E.coli as the bacteria E. coli has many advantages, such as inexpensive culturing, high expression levels and easy large scale production. All these advantages of the bacteria will consequentially serve to the development of more cost effective vaccines. Global Virus Like Particles Market & Clinical Trial Insight 2023 report highlights: The virus like particle based vaccines is commercially available in market against the hepatitis B virus and human papillomavirus. The viruses like particle based vaccines against several other viruses are in clinical development. The under trial vaccine candidates itself represents the target antigen and those in which the virus like particle is used to present the foreign antigens to immune system. The progresses have been made in developing virus like particle vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus and chikungunya virus. Currently there are 60 virus like particle vaccines in clinical trials and 5 virus like particle vaccines are commercially available in the market. The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies. The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry. 1. Virus like Particles - New Generation of Vaccines 1.1 Introduction 1.2 Requirements for Virus like Particles Assembly 2. Virus Candidates for Development of Virus like Particle Vaccines 2.1 Animal Virus-like Particles as Vaccine Immunogens 2.2 Plant Virus based Virus like Particles 3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases 3.1 HIV-1 Virus like Particles 3.2 Hepatitis C Virus 3.3 Malaria 3.4 Newcastle Disease 3.5 Filoviruses 3.6 Norovirus 4. Production Process of Virus like Particle based Vaccines 4.1 Expression Systems 4.2 Downstream Processing of Virus like Particle Based Vaccines 5. Market Analysis of Virus like Particles Vaccines 5.1 Introduction 5.2 Market of Virus like Particle Vaccines 6. Global Virus Like Particle Vaccines Clinical Pipeline Overview 7. Global Virus like Particle Vaccines Market Dynamics 7.1 Favorable Parameters 7.2 Commercialization Challenges 8. Future Perspective of Virus like Particles Vaccines 9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication & Phase 9.1 Research 9.2 Preclinical 9.3 Phase-I 9.4 Phase-I/II 9.5 Phase-II 9.6 Phase-II/III 9.7 Phase-III 10. Marketed Virus Like Particle Vaccines Clinical Insight 10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard) 10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix) 10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9) 10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S) 10.5 Influenza A Virus H1N1 Vaccine (CadiFlu) 11. Competitive Landscape 11.1 Agilvax 11.2 Allergy Therapeutics 11.3 ANGANY Genetics 11.4 CPL Biologicals 11.5 Cytos Biotechnology 11.6 GeoVax Labs 11.7 GlaxoSmithKline 11.8 Medicago 11.9 MedImmune 11.10 Merck 11.11 Novavax 11.12 Serum Institute of India 11.13 Takeda 11.14 TechnoVax 11.15 Xiamen Innovax Biotech For more information about this clinical trials report visit https://www.researchandmarkets.com/research/kccfzq/global_virus_like


The virus like particle based vaccines is commercially available in market against the hepatitis B virus and human papillomavirus. The viruses like particle based vaccines against several other viruses are in clinical development. The under trial vaccine candidates itself represents the target antigen and those in which the virus like particle is used to present the foreign antigens to immune system. The progresses have been made in developing virus like particle vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus and chikungunya virus. Currently there are 60 virus like particle vaccines in clinical trials and 5 virus like particle vaccines are commercially available in the market. The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies. The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry. 1. Virus like Particles - New Generation of Vaccines 1.1 Introduction 1.2 Requirements for Virus like Particles Assembly 2. Virus Candidates for Development of Virus like Particle Vaccines 2.1 Animal Virus-like Particles as Vaccine Immunogens 2.2 Plant Virus based Virus like Particles 3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases 3.1 HIV-1 Virus like Particles 3.2 Hepatitis C Virus 3.3 Malaria 3.4 Newcastle Disease 3.5 Filoviruses 3.6 Norovirus 4. Production Process of Virus like Particle based Vaccines 4.1 Expression Systems 4.2 Downstream Processing of Virus like Particle Based Vaccines 5. Market Analysis of Virus like Particles Vaccines 5.1 Introduction 5.2 Market of Virus like Particle Vaccines 6. Global Virus Like Particle Vaccines Clinical Pipeline Overview 7. Global Virus like Particle Vaccines Market Dynamics 7.1 Favorable Parameters 7.2 Commercialization Challenges 8. Future Perspective of Virus like Particles Vaccines 9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication & Phase 9.1 Research 9.2 Preclinical 9.3 Phase-I 9.4 Phase-I/II 9.5 Phase-II 9.6 Phase-II/III 9.7 Phase-III 10. Marketed Virus Like Particle Vaccines Clinical Insight 10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard) 10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix) 10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9) 10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S) 10.5 Influenza A Virus H1N1 Vaccine (CadiFlu) 11. Competitive Landscape 11.1 Agilvax 11.2 Allergy Therapeutics 11.3 ANGANY Genetics 11.4 CPL Biologicals 11.5 Cytos Biotechnology 11.6 GeoVax Labs 11.7 GlaxoSmithKline 11.8 Medicago 11.9 MedImmune 11.10 Merck 11.11 Novavax 11.12 Serum Institute of India 11.13 Takeda 11.14 TechnoVax 11.15 Xiamen Innovax Biotech For more information about this clinical trials report visit https://www.researchandmarkets.com/research/glmhbx/global_virus_like Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716


Manduzio H.,ANGANY Genetics | Fitchette A.-C.,ANGANY Genetics | Hrabina M.,Stallergenes SA | Chabre H.,Stallergenes SA | And 5 more authors.
Plant Biotechnology Journal | Year: 2012

Grass pollen allergic patients are concomitantly exposed and sensitized to pollens from multiple Pooideae (i.e. common grass) species. As such, they are currently desensitized by allergen-specific immunotherapy using extracts made from mixes of pollens from Anthoxanthum odoratum, Dactylis glomerata, Lolium perenne, Phleum pratense and Poa pratensis. Herein, we demonstrate that species-specific glycoprotein patterns are documented by 1D and 2D electrophoresis and Western blotting analysis, which can be used as an identity test for such pollens. Most allergens are glycoproteins bearing complex N-glycans encompassing β1,2 xylose and α1,3 fucose glycoepitopes. Glycoepitope destruction using periodate oxidation has no impact on seric IgE reactivity in 75% atopic patients (n=24). The latter have thus no significant IgE responses to carbohydrate-containing epitopes. In contrast, periodate treatment strongly impairs IgE recognition of glycoallergens in 25% of patients tested, demonstrating the presence of carbohydrate-specific IgE in those patients. While the clinical impact of carbohydrate-specific IgE is still a matter of controversy, the presence of these IgE in the serum of many allergic patients illustrates the need for cross-reacting carbohydrate epitope-free recombinant allergens to develop relevant diagnostic tests. These data also support the pertinence of mixing multiple grass pollens to desensitize atopic patients, with the aim to broaden the repertoire of glycoepitopes in the vaccine, thus mimicking natural exposure conditions. © 2011 Society for Experimental Biology, Association of Applied Biologists and Blackwell Publishing Ltd.


Gomord V.,University of Rouen | Fitchette A.,ANGANY Genetics | Menu-Bouaouiche L.,University of Rouen | Saint-Jore-Dupas C.,University of Rouen | And 3 more authors.
Plant Biotechnology Journal | Year: 2010

While . N-glycan synthesis in the endoplasmic reticulum (ER) is relatively well conserved in eukaryotes, . N-glycan processing and . O-glycan biosynthesis in the Golgi apparatus are kingdom specific and result in different oligosaccharide structures attached to glycoproteins in plants and mammals. With the prospect of using plants as alternative hosts to mammalian cell lines for the production of therapeutic glycoproteins, significant progress has been made towards the humanization of protein . N-glycosylation in plant cells. To date, successful efforts in this direction have mainly focused on the targeted expression of therapeutic proteins, the knockout of plant-specific . N-glycan-processing genes, and/or the introduction of the enzymatic machinery catalyzing the synthesis, transport and addition of human sugars. By contrast, very little attention has been paid until now to the . O-glycosylation status of plant-made therapeutic proteins, which is surprising considering that hundreds of human proteins represent good candidates for Hyp-. O glycosylation when produced in a plant expression system. This review describes protein . N- and . O-linked glycosylation in plants and highlights the limitations and advantages of plant-specific glycosylation on plant-made biopharmaceuticals. © 2010 The Authors. Journal compilation © 2010 Blackwell Publishing Ltd.


Patent
Angany Genetics | Date: 2013-06-13

A method for producing a recombinant protein in a plant, in particular a tobacco plant, preferably Nicotiana benthamiana, includes the following steps: a) culturing the plant aeroponically or hydroponically, preferably on mobile floats and under LED lighting; b) vacuum agroinfiltration of the plant obtained in a) by agrobacteria that include a DNA fragment coding for the recombinant protein; c) returning the plants to culturing after step b), under the same conditions as for step a); and d) extracting and purifying the recombinant protein from the aerial portions of the plants produced in step c).

Loading ANGANY Genetics collaborators
Loading ANGANY Genetics collaborators